REFERENCE
Srinivasulu Tirumalasetty
Global pharma News
WALK
IN DATE : 08/05/16
VENUE :
Biocon Campus
Hosur Road, Electronic City
Banglore
COMPANY :
JOB
LOCATION :
DEVISON
: Formulation
DEPARTMENTS: Production
QUALIFICATION : B.Pharm, M.Pharm,D.Pharm,B.Sc ,M.Sc
EXPERIENCE : 1 to 7 Years
Interest candidates send resume to ta.india@biocon.com
For more details go through below poster
About Us :
"Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realise the promise of future therapeutics."Kiran Mazumdar-Shaw, Chairperson & Managing Director Biocon, India's largest biotech company is focused on delivering affordable innovation.
It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Biocon's key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.
Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets.
Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 100 countries.
As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market.
Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene.
Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle.
"Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realise the promise of future therapeutics."Kiran Mazumdar-Shaw, Chairperson & Managing Director Biocon, India's largest biotech company is focused on delivering affordable innovation.
It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Biocon's key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, INSUGEN®, insulin analogue Glargine, BASALOG® and India's first indigenously produced monoclonal antibody BioMAb-EGFR®, for head & neck cancer. INSUPen® is a next generation affordable insulin delivery device introduced in India by Biocon.
Its aspiration to become a US $ 1 billion company by FY 18 is fuelled by five powerful growth accelerators, Small Molecules, Biosimilars, Branded Formulations, Novel Molecules, and Research Services with a focus on emerging markets.
Over the decades, Biocon has successfully evolved into an emerging global biopharma enterprise, serving its partners and customers in over 100 countries.
As a fully integrated biopharma company it delivers innovative biopharmaceutical solutions, ranging from discovery to development and commercialization, leveraging the cutting edge science, cost-effective drug development capabilities and global scale manufacturing capacities, to move ideas to market.
Leveraging India's globally competitive cost base and exceptional scientific talent, the Company is advancing its in-house R&D programs, and is also providing integrated research services to leading global pharmaceutical and biotechnology companies through Syngene and Clinigene.
Biocon has rapidly developed a robust novel and biosimilars pipeline, focusing on Diabetes, Oncology and auto-immune diseases, which has several molecules at different stages of the development cycle.
It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™(Itolizumab), a 'first in class' anti-CD6 monoclonal antibody. It has a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential Insulin Tregopil.
Thank you
for visiting my blog , Visit again for latest pharma updates.
No comments:
Post a Comment